Personalized Sarcoma Risk Tool Heads Into a Cluster Trial Across Dutch Hospitals
Treatment decisions in high-grade soft-tissue sarcoma are often made without individualized estimates of benefit and harm. In a disease where surgery, radiation, and other options can carry very different functional and oncologic consequences, the absence of patient-specific risk estimates leaves both clinicians and patients leaning on population averages and clinical judgment alone. The VALUE-PERSARC study was designed to test whether a personalized prediction tool can narrow that gap by improving patient knowledge and easing decisional conflict at the point where treatment plans are actually set.
The trial centers on PERSARC, a risk prediction tool intended to support discussions about treatment options for primary high-grade extremity soft-tissue sarcoma. Its purpose is straightforward: translate prognosis and treatment tradeoffs into individualized estimates that patients and professionals can use during multidisciplinary review and bedside consultation. In theory, that should make the advantages and harms of each option easier to compare, especially when a curative plan has not yet been chosen and the decision is still open.
Trial Design Targets the Consultation Itself
VALUE-PERSARC is a parallel cluster randomized controlled trial planned across six Dutch hospitals. Hospitals, rather than individual patients, will be randomized to usual care or to care supported by PERSARC. At least 120 primarily diagnosed patients with high-grade extremity sarcoma are expected to be included, a design choice that reflects the practical reality that the tool is meant to operate at the level of the clinical team and the consultation, not as a stand-alone patient device.
Eligibility is narrow by design. Participants must be adults, must have no treatment plan yet, and must be treated with curative intent. Patients with sarcoma subtypes or treatment options not represented in PERSARC are excluded, which keeps the intervention aligned with the tool’s actual modeling scope. In a setting where histology and anatomy can strongly shape what is even on the table, limiting enrollment to situations that fit the tool avoids overstating what the prediction model can do.
A cluster design also helps prevent contamination. If one clinician in a hospital uses the tool and another does not, the logic of the trial becomes muddled quickly. Randomizing whole hospitals gives the comparison a cleaner structure and mirrors how such a decision aid would be deployed in routine care.
PERSARC Will Be Used Where Sarcoma Decisions Are Made
Inside the intervention hospitals, PERSARC will be used by soft-tissue sarcoma professionals during multidisciplinary tumor board discussions and in patient consultations. The oncological or orthopaedic surgeon will explain the diagnosis and review the benefits and harms of relevant treatment options with the patient. That sequence matters because the tool is not being tested as a post hoc explanation. It is being inserted into the actual decision workflow, where uncertainty, anxiety, and tradeoffs are most acute.
The biological and clinical logic behind the study is grounded in the complexity of sarcoma care. High-grade extremity disease often presents a difficult balance between local control, function, and treatment burden. A patient may face major surgery, possible radiotherapy, and the downstream consequences of each approach. Personalized estimates may help convert broad treatment language into concrete risk information, which is often what patients need before they can meaningfully weigh one path against another.
One immediate question in sarcoma care is whether better information changes the decision experience itself.
Knowledge and Decisional Conflict Are the Primary Endpoints
The study’s primary outcomes are patient knowledge about the risks and benefits of treatment options and decisional conflict measured with the Decisional Conflict Scale one week after the treatment decision has been made. Choosing these endpoints puts the emphasis on whether the tool helps patients understand what is happening and whether it reduces the distress that often accompanies difficult choices. One week after the decision is a clinically relevant checkpoint: the treatment plan is settled, but the patient’s understanding of why that plan was chosen is still fresh enough to measure.
Knowledge and decisional conflict are closely linked but not identical. A patient can be well informed and still feel uncertain, or feel reassured without fully understanding tradeoffs. By measuring both, the trial is testing two different dimensions of decision quality. In sarcoma care, where the consequences of miscommunication can be large and lasting, that distinction is practical at the bedside.
Secondary outcomes will be collected by questionnaire at one week and again at 3, 6, and 12 months after the treatment decision. Those later time points should capture whether any early gains in understanding persist as treatment unfolds and as patients move from decision-making into surveillance, recovery, and longer-term follow-up.
Mixed-Model Analysis Will Account for Hospital-Level Clustering
The planned analysis uses an intention-to-treat approach with a linear mixed model that accounts for clustering of patients within hospitals. That matters because outcomes from the same institution are likely to be more similar than outcomes across different institutions, especially when local workflow, clinician experience, and multidisciplinary practices shape how PERSARC is introduced. Ignoring that structure would inflate confidence in the findings and blur the true effect of the intervention.
The economic question is embedded from the start. VALUE-PERSARC is not only asking whether the tool works in a communication sense, but whether it is cost-effective as well. For healthcare systems, that is a separate and necessary question. A tool that improves understanding but requires substantial implementation effort would need to justify its use against other ways of supporting shared decision-making.
A protocol cannot answer whether the tool will succeed, but it can show where the pressure points will be. If the intervention improves knowledge without reducing decisional conflict, the tool may be informing patients without fully easing uncertainty. If decisional conflict falls but knowledge does not rise, the mechanism may be psychological rather than informational. If both improve, PERSARC would have demonstrated a rare alignment between predictive modeling and patient-centered decision support.
Ethics Approval and Trial Registration Are in Place
The Medical Ethical Committee Leiden-Den Haag-Delft approved the protocol, and the study is registered under NL9160 and NCT05741944. Results are slated for publication in a peer-reviewed journal once the trial is complete.
For now, the study stands as a structured test of whether individualized prognostic information can change the experience of making a curative treatment decision in high-grade extremity soft-tissue sarcoma. The unanswered issue is not whether sarcoma decisions are difficult—they are—but whether a prediction tool can make those decisions clearer, less discordant, and more usable for the people who have to live with them.